Drawing for QIASTAT-DX

USPTO serial 88030446

QIASTAT-DX

Reviewed by CopyMark Law Group

Reg. 5761187Status 702Registered
Filing date
Status date
Registration date
May 28, 2019
Examiner
KEAM, ALEX S
Law office
Historical data usage

What this means

Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use. Continue use in commerce and plan for the 10-year Section 8 and 9 renewal.

Status 702: Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use.

Need help with QIASTAT-DX?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Daniel M. Gurfinkel

Daniel M. Gurfinkel Dennemeyer & Associates, LLC230 W. Monroe St.Suite 2100Chicago, IL 60606

Goods and services

ClassDescriptionStatusFirst use
001Chemical, biochemical and biotechnological reagents for industrial and scientific purposes; non-medical reagents, enzymes and buffer solutions for scientific and/or medical research use; Chemical reagents for sample preparation, modification and manipulation of cells and for marking, separating, isolating, purifying, duplicating, sequencing and/or for the analysis of biopolymers, in particular nucleic acids, proteins, macromolecules and biologically active substancesACTIVE—
005Diagnostic preparations for medical or veterinary purposes; diagnostic preparations for sample preparation, modification and manipulation of cells and for marking, separating, isolating, purifying, duplicating, sequencing and/or for the analysis of biopolymers, in particular nucleic acids, proteins, macromolecules and biologically active substances; cartridges sold pre-filled with reagents and/or liquids for medical and medical diagnostic use; cartridges sold pre-filled with reagents for sample preparation and analysis for medical or veterinary diagnostic use; Single-use cartridges for medical diagnostic purposes, containing reagents and/or liquids for sample preparation, modification and manipulation of cells and for marking, separating, isolating, purifying, duplicating, sequencing and/or for the analysis of biopolymers; cartridges sold pre-filled with reagents for breaking of cell material, nucleic acid purification, amplification and hybridization for medical or medical diagnostic useACTIVE—
009Single-use cartridges for clinical laboratory use containing nucleic acid extraction column and/or real time Polymerase Chain Reaction chambersACTIVE—
010Medical diagnostic apparatus and instruments for use in preparing blood, bodily fluid and human biological samples for further testing and for the detection and identification of pathogen nucleic acids in blood, bodily fluids and biological samples; Analyzers for medical use for analyzing blood, bodily fluids and human biological samples; Analyzers for medical diagnosis for analyzing blood, bodily fluids and human biological samples; Medical and clinical diagnosis apparatus and machines, namely, molecular and immunoassay analyzers for analyzing blood and bodily fluids; Testing instruments for medical diagnostic purposes, namely, analyzers for detection and identification of pathogen nucleic acids in blood, bodily fluids and human biological samples; Apparatus for carrying-out diagnostic tests for medical purposes for testing blood bodily fluids and human biological samplesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 2, 2025NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
Sep 2, 2025C15AREGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
Sep 2, 2025APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Apr 25, 2025E815TEAS SECTION 8 & 15 RECEIVED—
May 28, 2024REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
May 28, 2019R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Mar 12, 2019NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Mar 12, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 20, 2019NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Feb 5, 2019CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Feb 5, 2019XAECEXAMINER'S AMENDMENT ENTERED—
Feb 5, 2019GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Feb 5, 2019GNEAEXAMINERS AMENDMENT E-MAILED—
Feb 5, 2019CNEAEXAMINERS AMENDMENT -WRITTEN—
Jan 30, 2019ZZZXPREVIOUS ALLOWANCE COUNT WITHDRAWN—
Jan 22, 2019PBCRWITHDRAWN FROM PUB - OG REVIEW QUERY—
Jan 9, 2019PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Jan 7, 2019CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 7, 2019XAECEXAMINER'S AMENDMENT ENTERED—
Jan 7, 2019GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jan 7, 2019GNEAEXAMINERS AMENDMENT E-MAILED—
Jan 7, 2019CNEAEXAMINERS AMENDMENT -WRITTEN—
Oct 31, 2018GPRNNOTIFICATION OF PRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Oct 31, 2018GPRAPRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Oct 31, 2018CPRAPRIORITY ACTION WRITTENA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Oct 26, 2018DOCKASSIGNED TO EXAMINER—
Sep 11, 2018AMPXPRELIMINARY/VOLUNTARY AMENDMENT - ENTERED—
Sep 6, 2018ALIEASSIGNED TO LIE—
Aug 23, 2018PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Aug 23, 2018PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Jul 13, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jul 12, 2018NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance